NCT03628677 2025-02-04
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
Arcus Biosciences, Inc.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Artios Pharma Ltd